 |
|
Clinicopathologic Features of Retinoblastoma After Primary Chemoreduction
Nikolaos E. Bechrakis, MD;
Norbert Bornfeld, MD;
Andreas Schueler, MD;
Sarah E. Coupland, MBBS, PhD;
Guenter Henze, MD;
Michael H. Foerster, MD
Arch Ophthalmol. 1998;116:887-893.
Background Primary chemotherapy is a new treatment approach in retinoblastoma, aiming to avoid radiogenic adverse effects, such as second tumor–associated mortality, as observed following external beam irradiation.
Objective To describe the clinical and histopathologic regression pattern after primary chemotherapy in retinoblastoma.
Methods Five patients with sporadic bilateral retinoblastoma underwent planned enucleation of their functionally blind eye after 2, 3 (in 2 patients), 4, and 6 courses of primary chemotherapy with carboplatin, etoposide, cyclophosphamide, and vincristine. The eyes were examined histopathologically, using light microscopy and immunohistochemical analysis with proliferation markers.
Results One patient had a type 1 (cottage cheese) regression and 4 patients had either a type 2 (fish flesh) or a type 3 (combined) regression pattern. Histopathologic examination revealed a complete tumor necrosis in 1 patient with type 1 regression after 3 courses of chemotherapy and in 1 patient with type 3 regression after 4 courses of chemotherapy. The remaining 3 patients with type 2 or type 3 regression had histologically still active proliferative tumor cells after 2, 3, and 6 courses of chemotherapy.
Conclusion This article correlates histopathologically the clinically described efficacy of primary chemotherapy in the treatment of retinoblastoma, underlining, however, the necessity of careful observation and the use of ancillary treatment whenever there is no complete tumor regression.
From the Departments of Ophthalmology (Drs Bechrakis and Foerster) and Pathology (Dr Coupland), Klinikum Benjamin Franklin, Free University of Berlin; Department of Ophthalmology (Drs Bornfeld and Schueler), University of Essen, Essen, Germany; and the Department of Pediatric Oncology-Hematology, Virchow-Klinikum, Humboldt University (Dr Henze), Berlin, Germany.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Retinoblastoma Regression Patterns Following Chemoreduction and Adjuvant Therapy in 557 Tumors
Shields et al.
Arch Ophthalmol 2009;127:282-290.
ABSTRACT
| FULL TEXT
Retinoblastoma and optic nerve enhancement on MRI: not always extraocular tumour extension
de Graaf et al.
Br J Ophthalmol 2006;90:800-801.
FULL TEXT
Histopathological Features and P-glycoprotein Expression in Retinoblastoma
Filho et al.
IOVS 2005;46:3478-3483.
ABSTRACT
| FULL TEXT
Regarding Chemoreduction for Retinoblastoma and Intracranial Neoplasms--Reply
Schouten-van Meeteren et al.
Arch Ophthalmol 2004;122:1571-1571.
FULL TEXT
Globe conserving treatment of the only eye in bilateral retinoblastoma
Lee et al.
Br J Ophthalmol 2003;87:1374-1380.
ABSTRACT
| FULL TEXT
Chemoreduction for Retinoblastoma
Moll et al.
Arch Ophthalmol 2003;121:1513-1513.
FULL TEXT
Histopathologic Findings in Eyes With Retinoblastoma Treated Only With Chemoreduction
Demirci et al.
Arch Ophthalmol 2003;121:1125-1131.
ABSTRACT
| FULL TEXT
Thermochemotherapy in hereditary retinoblastoma
Schueler et al.
Br J Ophthalmol 2003;87:90-95.
ABSTRACT
| FULL TEXT
Hyperfractionated External Beam Radiation Therapy in the Treatment of Murine Transgenic Retinoblastoma
Hayden et al.
Arch Ophthalmol 2002;120:353-359.
ABSTRACT
| FULL TEXT
Chemoreduction for Retinoblastoma May Prevent Trilateral Retinoblastoma
Shields et al.
JCO 2000;18:236-236.
FULL TEXT
|
